Please login to the form below

Not currently logged in
Email:
Password:

Bentley wins US intranasal technology patent protection

Bentley Pharmaceuticals has revealed that the US Patent and Trademark Office issued it with patent protection on its intranasal technology

US-based specialty pharmaceutical company, Bentley Pharmaceuticals, has received US Patent and Trademark Office recognition through the award of patent number 7,244,703 entitled "Pharmaceutical Compositions and Methods for Peptide Treatment."

The patent extends coverage for Bentley's current intranasal drug delivery technology employing CPE-215 beyond insulin to include delivery of other therapeutically effective, pharmaceutically active peptides, peptidomimetics and proteins.

In September 2006, Bentley received a US patent covering its intranasal delivery spray for insulin.

The new patent, which was issued from an application filed back in 2004, provides proprietary protection to Bentley for 20 years from the date of filing.

23rd July 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Evoke Kyne

Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...